Analysis of therapeutic effect of cell reduction combined with intraperitoneal thermoperfusion chemotherapy in treatment of peritoneal pseudomyxoma

Table 1 Status of 186 cases of pseudomyxoma of abdominal cavity treated by cell reduction combined with intraperitoneal hyperthermic chemotherapy, n (%)

Variable	Number of cases
Primary site
Appendix	170 (91.4)
Ovary	15 (8.1)
Location	1 (0.5)
Pathological type
Low-level	99 (53.2)
High level	57 (30.6)
Not quite clear	30 (16.1)
Lymph node metastasis
Correct	19 (10.2)
Deny	151 (81.2)
Suspicious transfer	16 (8.6)
Meningeal tumor index score
≤ 10	7 (3.8)
11-20	34 (18.3)
21-30	56 (30.1)
31-39	55 (29.6)
Not quite clear	34 (18.3)
CCR rating
CCR-0	15 (8.1)
CCR-1	40 (21.5)
CCR-2/3	113 (60.8)
Not quite clear	18 (9.7)
Whether to combine organ resection
Correct	123 (66.1)
Deny	63 (33.9)
HIPEC count
1	30 (16.1)
2	48 (25.8)
3	79 (42.5)
4	25 (13.4)
5	4 (2.2)
HIPEC drugs
Raltitrexed	47 (25.3)
Letotrexate + Oxaliplatin + Mitomycin	42 (22.6)
Platinum	32 (17.2)
Letotrexate + Oxaliplatin	25 (13.4)
Letotrexate + Mitomycin	20 (10.8)
Mitomycin	8 (4.3)
Oxaliplatin + Mitomycin	8 (4.3)
Other	4 (2.2)

HIPEC: Intraperitoneal hyperthermic chemotherapy; CCR: Cell reduction degree.